Butyrolactone I

SKU: orb1305365

Description

Butyrolactone I (Olomoucin) is a potent, ATP-competitive inhibitor of CDK and cdc2 kinase families. It has demonstrated antitumor activity in vitro against various cancer cell lines, including non-small cell lung, small cell lung, and prostate cancers, making it a valuable tool for cell cycle and oncology research.

Research Area

Cell Biology, Immunology & Inflammation, Signal Transduction

Key Properties

• CAS Number: 87414-49-1
• MW: 424.44
• Purity: 98.00% (May vary between batches)
• Formula: C₂₄H₂₄O₇
• SMILES: COC(=O)[C@]1(Cc2ccc(O)c(CC=C(C)C)c2)OC(=O)C(O)=C1c1ccc(O)cc1
• Target: CDK,PERK,ROS,Bcl-2 Family,Apoptosis,NF-κB
• Solubility: DMSO:80 mg/mL (188.48 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (7.77 mM)

Bioactivity

• In Vitro:
  Butyrolactone I (70 and 100 μM) increases the percentage of DU145 cells in the 4C phase of the cell cycle. Butyrolactone I increases the amount of cyclin B1 positive cells in the 4C phase on day 1 and returns to normal by day 3. Butyrolactone I inhibits Cdc2 of unsynchronized cultured prostate cancer cells and interrupts the cell cycle progression toward cell division. The Butyrolactone I inhibition of Cdc2 led to the accumulation of cells in the 4C phase without mitosis resulting in an accumulation of cyclin B1.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CDK2, Cdc2/CyclinB, Butyrolactone I, Olomoucin

Compound Identifiers

PubChem CID

123740